REGEND001

BIOLOGICAL3 trials

Sponsors

Regend Therapeutics

Conditions

COPD (Chronic Obstructive Pulmonary Disease)Idiopathic Pulmonary Fibrosis

Phase 1

Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND001

CompletedNCT05657184

Regend TherapeuticsIdiopathic Pulmonary Fibrosis

Start: 2021-07-19End: 2023-06-09Updated: 2024-07-08

Phase 2

A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF)

CompletedNCT06081621

Regend TherapeuticsIdiopathic Pulmonary Fibrosis

Start: 2023-12-11End: 2025-03-14Updated: 2026-03-18

Phase 3

A Clinical Study of REGEND001 for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Not yet recruitingNCT07828353

Regend TherapeuticsCOPD (Chronic Obstructive Pulmonary Disease)

Start: 2026-10-01End: 2028-09-01Target: 102Updated: 2026-09-18